论文部分内容阅读
目的:探讨老年冠心病合并高脂血症应用剂量不同的瑞舒伐他汀钙治疗的临床效果。方法:以随机数字表法,随机将2015年7月-2016年3月期间于我院实施治疗的老年冠心病合并高脂血症患者78例分为两组,均采用瑞舒伐他汀钙治疗,其中对照组(n=39例)应用小剂量,而观察组(n=39例)则应用大剂量,对比分析,不同用药剂量对疾病的治疗效果。结果:干预前,HDL-C、LDL-C、TG、TC指标水平无明显差异(p>0.05),干预后均优于干预前(p<0.05),组间干预后对比,观察组HDL-C明显比对照组高(p<0.05),LDL-C、TG、TC水平明显比对照组低(p<0.05);观察组治疗期间皮疹、关节疼痛、肌肉酸痛发生率稍高于对照组,但是,并无明显差异(p>0.05)。结论:老年冠心病合并高脂血症患者临床治疗应用瑞舒伐他汀钙时,用药剂量设定为20mg/d,可在一定程度上提升疗效,充分发挥药品价值。
Objective: To investigate the clinical effect of rosuvastatin calcium in elderly patients with coronary heart disease complicated with hyperlipidemia. Methods: According to the random number table method, 78 elderly patients with coronary heart disease and hyperlipidemia who were treated in our hospital from July 2015 to March 2016 were randomly divided into two groups, all treated with rosuvastatin calcium (N = 39), and the observation group (n = 39) received high dose, comparative analysis and the effect of different dosage on the disease. Results: Before intervention, the levels of HDL-C, LDL-C, TG and TC had no significant difference (p> 0.05), and were better than those before intervention (p <0.05) C significantly higher than the control group (p <0.05), LDL-C, TG, TC levels were significantly lower than the control group (p <0.05); rash, joint pain and muscle ache during the treatment group was slightly higher than the control group, However, there was no significant difference (p> 0.05). Conclusion: The clinical treatment of elderly patients with coronary heart disease and hyperlipidemia when rosuvastatin calcium, the dose was set to 20mg / d, to a certain extent, enhance the efficacy and give full play to the value of drugs.